Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Marcellin

Showing results (191-200 of 212) with videos related to

Pageof 22
Sort By:
Gut|August 13, 2009
Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4R Moucari, M-P Ripault, M Martinot-Peignoux, et al.
Alimentary Pharmacology & Therapeutics|December 18, 2007
Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis CJ G McHutchison, K Patel, E R Schiff, et al.
Gut|November 28, 2006
Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis BF Bonino, P Marcellin, G K K Lau, et al.
Journal of Viral Hepatitis|December 17, 2013
Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countriesH Leblebicioglu, V Arama, X Causse, et al.
Journal of Viral Hepatitis|October 18, 2013
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohortA Aronsohn, I Ancuta, F Caruntu, et al.
Alimentary Pharmacology & Therapeutics|October 13, 2017
HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patientsD Wong, M Littlejohn, L Yuen, et al.
Clinical Biochemistry|June 16, 2001
Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis CM G Neuman, J P Benhamou, I M Malkiewicz, et al.
Alimentary Pharmacology & Therapeutics|August 16, 2006
Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective studyC Bonny, H Fontaine, T Poynard, et al.
Journal of Viral Hepatitis|December 22, 1999
Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEPM Martinot-Peignoux, F Roudot-Thoraval, I Mendel, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple TherapyC Laouénan, J Guedj, G Peytavin, et al.
Pageof 22

Showing results (191-200 of 212) with videos related to

Sort By:
Pageof 22
Gut|August 13, 2009
Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4R Moucari, M-P Ripault, M Martinot-Peignoux, et al.
Alimentary Pharmacology & Therapeutics|December 18, 2007
Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis CJ G McHutchison, K Patel, E R Schiff, et al.
Gut|November 28, 2006
Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis BF Bonino, P Marcellin, G K K Lau, et al.
Journal of Viral Hepatitis|December 17, 2013
Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countriesH Leblebicioglu, V Arama, X Causse, et al.
Journal of Viral Hepatitis|October 18, 2013
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohortA Aronsohn, I Ancuta, F Caruntu, et al.
Alimentary Pharmacology & Therapeutics|October 13, 2017
HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patientsD Wong, M Littlejohn, L Yuen, et al.
Clinical Biochemistry|June 16, 2001
Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis CM G Neuman, J P Benhamou, I M Malkiewicz, et al.
Alimentary Pharmacology & Therapeutics|August 16, 2006
Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective studyC Bonny, H Fontaine, T Poynard, et al.
Journal of Viral Hepatitis|December 22, 1999
Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEPM Martinot-Peignoux, F Roudot-Thoraval, I Mendel, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple TherapyC Laouénan, J Guedj, G Peytavin, et al.
Pageof 22